Cancer Therapy News and Research

RSS

Calypso System can precisely deliver radiation in post-prostatectomy patients

Calypso Medical Technologies, Inc., developer of GPS for the Body® technology used for the precise tracking of cancerous tumors during radiation therapy, is exhibiting at the American Urological Association Annual Meeting (booth 4337) and will discuss recent clinical findings suggesting that the Calypso® System can be used to more precisely deliver radiation in post-prostatectomy patients.

16 May 2011

Young scientists receive Intel Foundation top prize for groundbreaking cancer work

Matthew Feddersen and Blake Marggraff from Lafayette, Calif. were awarded the top prize at the Intel International Science and Engineering Fair, a program of Society for Science & the Public. They received $75,000 and the Gordon E. Moore Award, in honor of the Intel co-founder and retired chairman and CEO, for developing a potentially more effective and less expensive cancer treatment that places tin metal near a tumor before radiation therapy.

16 May 2011

Obese men may face high risk of prostate cancer progression

Even when treated with hormone therapy to suppress tumor growth, obese men face an elevated risk of their prostate cancer worsening, researchers at Duke University Medical Center have found.

16 May 2011

Pro-Pharmaceuticals reports net loss of $2.7 million for first quarter 2011

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the first quarter, ended March 31, 2011.

13 May 2011

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.

13 May 2011

TFAH applauds HHS for new strategic approach to prevent viral hepatitis

The Trust for America's Health applauds the U.S. Department of Health and Human Services for unveiling a new strategic approach to dealing with the silent epidemic of viral hepatitis today.

13 May 2011

Groundbreaking cancer treatment studies to be unveiled at AAPS National Biotechnology Conference

Cancer studies from Mercer University headline groundbreaking research that will be unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference (NBC).

13 May 2011

Health Canada approves EMEND IV formulation to prevent chemotherapy-induced nausea, vomiting

Today Merck announced that Health Canada has approved the new intravenous formulation of EMEND IV. Used in combination with a 5-HT3 antagonist class of antiemetics and dexamethasone, fosaprepitant dimeglumine is indicated for the prevention of acute and delayed nausea and vomiting due to highly emetogenic cancer chemotherapy.

12 May 2011

Researchers look for surrogate endpoints to predict early benefit of cancer drugs

Great hopes are always placed in new cancer therapies. However, whether new surgical techniques, drugs or radiation therapies actually prolong the life of cancer patients, or even cure them, can often only be reliably assessed after several years' of testing. Researchers are therefore looking for proxy markers that after initiation of cancer therapy can reliably predict as quickly as possible whether the treatment has a benefit.

12 May 2011

INESC Porto, FC and FMUP to hold international seminar on breast cancer local treatment

The international seminar "Turning Subjective Into Objective: Cosmetic Breast Assessment of Local Treatment" will take place on 13th May starting at 9.15am. The event is organised by the Champalimaud Foundation, the Faculty of Medicine of the University of Porto and the Institute for Systems and Computer Engineering of Porto.

12 May 2011

Women with invasive breast cancer can benefit from new genomic test

A new genomic test combining multiple signatures - a patient's estrogen receptor status, endocrine therapy response, chemotherapy resistance and sensitivity - shows promise as a predictor of chemotherapy response and survival benefit in women with invasive breast cancer, according to research led by The University of Texas MD Anderson Cancer Center.

11 May 2011

U.S. veterans over 70 and older can benefit from current colon cancer screening methods

A new study of U.S. veterans ages 70 and older finds that the healthiest get the most benefit from current colon cancer screening methods. However, for many less healthy veterans the burdens of screening may outweigh the benefits.

10 May 2011

Hitachi to provide Mayo Clinic with two sets of proton beam therapy systems

Hitachi, Ltd. today announced that it has entered into an agreement to provide Mayo Clinic with its proton beam therapy (PBT) system. This next-generation technology has spot scanning capability for treating certain forms of cancer. The agreement includes PBT system maintenance for both facilities for 10 years following completion of the systems' installation.

10 May 2011

Three Ontario projects set to further knowledge and discovery in biomonitoring, drug development

As part of the Genome Canada Large-Scale Applied Research Project Competition, which as a whole awarded over $58 million to 16 projects across the country, the researchers in Ontario will be focusing on biomonitoring, understanding gene function with the aim of identifying genes or proteins for drug targets, and the creation of synthetic antibodies to target cancers and other diseases.

9 May 2011

OncoSec's tumor-destroying, tissue-sparing drug/device system profiled in Medical Device Daily

OncoSec Medical Inc., a therapeutic oncology company developing innovative medical approaches to treat solid tumor cancers with unmet medical needs, announced today the cancer therapy company's tumor-destroying, tissue-sparing drug/device technology was profiled in Medical Device Daily, the news source for the high-tech medical technology industry that is relied on by thousands of industry insiders every business morning.

9 May 2011

Mary Ann Liebert publishes new journal on cancer care for adolescent and young adult patients

The field of adolescent and young adult oncology reflects the growing recognition that this group of patients and survivors are not just "old" pediatric patients or "young" adult patients.

9 May 2011

Theragenics reports consolidated revenue of $20.3 million for first quarter 2011

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the first quarter ended March 31, 2011.

5 May 2011

Clinical study: Celecoxib drug may treat breast cancer

The anti-inflammatory drug celecoxib may be a useful additional treatment for people with breast cancer, Dutch researchers report at the IMPAKT Breast Cancer Conference in Brussels.

5 May 2011

Research experts to speak at brain tumor educational conference

Patients, families and caregivers are invited to attend an educational conference covering many aspects of brain tumors May 14 at Cedars-Sinai Medical Center.

5 May 2011

Childhood cancer survivors may face high risk of late GI complications after therapy

Patients who received therapy for cancer during childhood have an increased risk of developing gastrointestinal complications later in life, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association Institute.

5 May 2011

Cancer Therapy News and Research

Calypso System can precisely deliver radiation in post-prostatectomy patients

Young scientists receive Intel Foundation top prize for groundbreaking cancer work

Obese men may face high risk of prostate cancer progression

Pro-Pharmaceuticals reports net loss of $2.7 million for first quarter 2011

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

TFAH applauds HHS for new strategic approach to prevent viral hepatitis

Groundbreaking cancer treatment studies to be unveiled at AAPS National Biotechnology Conference

Health Canada approves EMEND IV formulation to prevent chemotherapy-induced nausea, vomiting

Researchers look for surrogate endpoints to predict early benefit of cancer drugs

INESC Porto, FC and FMUP to hold international seminar on breast cancer local treatment

Women with invasive breast cancer can benefit from new genomic test

U.S. veterans over 70 and older can benefit from current colon cancer screening methods

Hitachi to provide Mayo Clinic with two sets of proton beam therapy systems

Three Ontario projects set to further knowledge and discovery in biomonitoring, drug development

OncoSec's tumor-destroying, tissue-sparing drug/device system profiled in Medical Device Daily

Mary Ann Liebert publishes new journal on cancer care for adolescent and young adult patients

Theragenics reports consolidated revenue of $20.3 million for first quarter 2011

Clinical study: Celecoxib drug may treat breast cancer

Research experts to speak at brain tumor educational conference

Childhood cancer survivors may face high risk of late GI complications after therapy

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News